Sirion advances two products into Phase III

Article

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

The programmes will evaluate ST-601 as a therapy for the treatment of anterior uveitis and ST-603 as a potential therapy for dry eye syndrome.

The addition of these two Phase III studies brings the number of Sirion's active clinical programmes to five.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A woman stands at a mirror, inserting a contact lens. Image credit: ©Camerene Pendl/peopleimages.com – stock.adobe.com

Bausch + Lomb launches Arise orthokeratology lens fitting system in Europe, UK and US

Jordana Joy
March 17th 2025
Article

The Arise system utilises advanced algorithms to interpret corneal topography images, recommending lenses without requiring a fitting set

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An image of the old town in Winterthur, Switzerland, showing buildings and clock towers. Image credit: ©bill_17 – stock.adobe.com

Winterthur, Switzerland welcomes second annual Winterthur Ophthalmology Symposium

Hattie Hayes
March 14th 2025
Article

After a successful inaugural WOS in 2024, the congress will feature new lectures and wetlabs in its sophomore year

An eye doctor administers cyclosporine eye drops to a patient. Image credit: ©smile35 – stock.adobe.com

Study assesses efficacy of cyclosporine A 0.1% cationic emulsion drops for postoperative discomfort

Lynda Charters
March 14th 2025
Article

Prophylactic cyclosporine A 0.1% eye drops were associated with improved ocular surface homeostasis and reduced inflammation

Wooden blocks which say PHASE and a block at the end with the numbers 1/2. The last block is switching from 1 to 2. This represents a clinical trial moving through phases. Image credit: ©rabbitti – stock.adobe.com

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Hattie Hayes
March 13th 2025
Article

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

Figure. Slit-scanning in vivo confocal microscopy images of the corneal endothelium: A (left) demonstrates a healthy control cornea: Image of a normal corneal endothelium, showing a uniform hexagonal cell pattern with consistent cell density and no visible guttae or abnormalities (white solid arrowhead). B (right) shows FECD: Increased confluency of guttata, illustrating a more extensive presence of these structures. Images courtesy UCL/NIHR Moorfields Biomedical Research Centre.

Study links new gender and genetic factors to Fuchs Endothelial Corneal Dystrophy

Hattie Hayes
March 13th 2025
Article

A large-scale study indicates women are more likely to develop the inherited corneal condition

© 2025 MJH Life Sciences

All rights reserved.